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Background: The hemizygous 22q11.2 micro-deletion is a common 
copy number variant in humans. The deletion confers high risk 
of neurodevelopmental disorders including autism and 
schizophrenia. Up to 41% of deletion carriers experience 
psychotic symptoms. Methods: We present a new mouse model 
(Df(h22q11)/+) of the deletion syndrome (22q11.2DS) and report 
on the most comprehensive study undertaken in 22q11.2DS 
models. The study was conducted in male mice. Results: We 
found elevated post-pubertal NMDA receptor antagonist induced 
hyper-locomotion, age-independent prepulse inhibition (PPI) 
deficits and increased acoustic startle response (ASR). The 
PPI deficit and increased ASR was resistant to antipsychotic 
treatment. The PPI deficit was not a consequence of impaired 
hearing measured by auditory brain stem responses. The 
Df(h22q11)/+ mice also displayed increased amplitude of 
loudness-dependent auditory evoked potentials. Prefrontal 
cortex and dorsal striatal (DStr) elevations of the dopamine 
metabolite DOPAC and increased DStr expression of the AMPA 
receptor subunit GluR1 was found. The Df(h22q11)/+ mice did 
not deviate from wild-type mice in a wide range of other 
behavioural and biochemical assays. Limitations: The 22q11.2 
micro-deletion has incomplete penetrance in humans and the 
severity of disease depends on the complete genetic makeup in 
Page 4 of 83
For Peer Review Only































































concert with environmental factors. In order to obtain more 
marked phenotypes reflecting the severe conditions related to 
22q11.2DS it is suggested to expose the Df(h22q11)/+ mice to 
environmental stressors which may unmask latent 
psychopathology. Conclusion: The Df(h22q11)/+ model will be a 
valuable tool for increasing our understanding of the 
aetiology of schizophrenia and other psychiatric disorders 
associated with the 22q11DS. 
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The 22q11.2 hemizygous micro-deletion confers very high 
risk of neurodevelopmental disorders including autism and 
schizophrenia (22q11.2 deletion syndrome - 22q11.2DS). The 
estimated prevalence is approximately 1:2000 (1). The 
International Consortium on Brain and Behavior in 22q11.2 has 
recently reported the cumulated prevalence of schizophrenia to 
be 24% in adolescence and 41% in adulthood (2). Studies of 
schizophrenia patients find that 22q11.2 deletion account for 
approximately 0.3% of the cases (3). 
Despite massive efforts there is still no coherent 
understanding of the aetiology of schizophrenia - a highly 
heritable heterogeneous disorder with strong environmental 
influence (4;5). Several neurotransmitters are implicated in 
the disorder: Glutamate (6), GABA- (7), dopamine- (DA) (8), 
and acetylcholine- signaling (9) have all been implicated in 
the disease aetiology and manifestation. The cognitive 
impairment and negative symptomatology have been related to 
dysfunction in regulation of glutamate-GABA transmission 
leading to excitatory-inhibitory imbalances (7). Like in 
schizophrenia(10;11), cognition (12) and information 
processing is disrupted in children with 22q11.2 deletion, who 
have not (yet) developed schizophrenia (13;14). Due to the 
highly increased risk of developing schizophrenia and the 
phenotypic overlap between schizophrenia and the 22q11.2DS, 
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studies of the consequence of the 22q11.2 deletion provides a 
unique opportunity to add to the understanding of the 
aetiology of schizophrenia and other related psychiatric 
disorders, which eventually may lead to novel drugs targeting 
the core of the disease. 
Five transgenic mouse models of the 22q11.2DS have been 
generated by different research groups (Table 1). These models 
have recently been reviewed by Hiroi et al. that also provide 
an overview of key genes in the 22q11 region (15). 
Inconsistent results are reported from assays addressing 
schizophrenia-relevant cognitive functions (Unpublished 
observations) whereas studies of other symptom domains are 
more consistent (see Table 1). Decreased prepulse inhibition 
(PPI) and increased acoustic startle response (ASR) is 
consistently observed (LgDel (16), Df1/+ (17) and Df(16)A+/-) 
(18). However, hearing was recently shown to be impaired in 
the Df1/+ mouse (19), raising the possibility that hearing 
loss rather than altered sensorimotor gating might underlie 
PPI deficits in 22q11DS mouse models. 
The LgDel (16), Df1/+ (17) and Df(16)A+/- (18) mice used 
in the referred studies are non-congenic. Genetic background 
(20) and environmental factors (21) may influence phenotypic 
expression. To be able to control for these factors and to 
ensure sufficient access to mice we have generated a new 
congenic mouse model (Df(h22q11)/+) of the 22q11.2DS as part 
of a large multi-site collaboration. Here we report on an 
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extensive characterisation of these mice using a set of assays 
related to the pathophysiology of schizophrenia. We find that 
the Df(h22q11)/+ mice display phenotypes relevant for 
modelling aspects of schizophrenia-related symptoms including 
increased post-pubertal NMDA antagonist sensitivity and age-
independent PPI and ASR deficits. We show that these 
impairments were not a result of impaired hearing. The 
Df(h22q11)/+ mice also displayed increased amplitude of 
loudness dependent auditory evoked potentials (LDAEP), 
prefrontal cortex (PFC) and dorsal striatal (DStr) elevations 
of the DA metabolite DOPAC, and increased DStr expression of 
the AMPA receptor subunit GluR1. The Df(h22q11)/+ mice did not 
deviate from wild-type (WT) mice in a range of other 
behavioural and biochemical assays. 
 
 
Materials and methods 
See Supplement for details. 
 
Animals 
The Df(h22q11)/+ mouse line was generated by 
TaconicArtemis (Köln, Germany). Animals were bred by mating WT 
C57BL/6N females with hemizygotic Df(h22q11)/+ males to avoid 
any placental or maternal care effects of the deletion. 
Animals were weaned at 3 weeks and tail biopsies were 
collected for PCR based genotyping. Mice were group-housed (2 
WT mice and 2 hemizygotes from the same litter per cage) under 
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controlled laboratory conditions (12:12 hr light-dark cycle; 
20±2°C; 30–70% humidity) in standard mouse cages with sawdust 
bedding, environmental enrichment (plastic house and paper for 
nesting), and food and water available ad libitum. Post-
surgery mice were single housed (see appendix – loudness 
dependence auditory evoked potentials. All experiments were 
carried out using littermate controls. The experiments used 27 
cohorts (N=12-95) of male mice aged 6-26 weeks (Figure A2). 
The selection of cohorts and animals for individual 
experiments was not randomized. All studies were carried out 
in accordance with the local legislation according to the 
European Union regulation (directive 2010/63 of 22 September 
2010) and UK Animals (Scientific Procedures) Act 1986. The 
studies were approved by the Barcelona School of Medicine 
Institutional Animal Care and Use Committee or the Danish 
National Committee for Ethics in Animal Experimentation. 
 
Drugs 
Clozapine (obtained from Novartis) was dissolved in 0.1 M 
hydrochloride and diluted with saline. Gabazine (SR95531, 
obtained from Sigma-Aldrich, St Louis, MO) was dissolved in 
0.2 M NaCl. Haloperidol (obtained from Sigma) was dissolved in 
0.1 M tartaric acid and diluted with saline. 
Phencyclidine (PCP), hydrochloride (synthesised by Lundbeck) 
was dissolved in 0.1 M methanesulfonic acid and diluted with 
saline. (S)-(+)-ketamine (obtained from Sigma-Aldrich) was 
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dissolved in 5% (w/v) glucose solution at a concentration of 
10 mg/ml. 
For the microdialysis studies veratridine and PCP were 
purchased from Sigma-Aldrich (Madrid, Spain) and nomifensine 
from Tocris (Madrid, Spain). Veratridine was dissolved in DMSO 
(5 mM) and nomifensine (1 mM) in artificial cerebrospinal 
fluid (aCSF). 
 
 Basal characterisation. Animals were characterised in the 
hot plate, rotarod, beam-walk, bright open-field, locomotor 
activity, and elevated plus maze. 
 
Prepulse Inhibition (PPI) of the acoustic startle 
response (ASR). The procedure is extensively described 
elsewhere (22). Six cohorts of animals were tested without 
drug treatment (age: 6-21 weeks). Two cohorts were treated 
with either clozapine (s.c. 10 ml/kg; 13-weeks old) or 
haloperidol (s.c. 10 ml/kg; 15-weeks old). 
 
NMDAr antagonist induced hyperactivity. Following a 60 
min habituation phase to a novel environment, Df(h22q11)/+ and 
WT littermates were treated with PCP or S(+)-ketamine (s.c. 10 
ml/kg) and their activity was monitored for a further 60 min. 
 
Anatomy. Gross characterisation including assessment of 
brain weight, ventricular size, hippocampal structure, 
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myelination, cortical thickness and layer composition using 
cortical NeuN and parvalbumin immunoreactivity and solochrome 
staining was conducted. 
 
Western analyses. A targeted screen (Peggy–Simple Western 
analyses) was carried out for proteins in the PFC, DStr and 
hippocampus. Markers showing significant changes across 
genotypes were replicated twice. The first replication used 
new dilutions from each of the 11 samples per genotype 
separately, while the second replication used 1 pooled sample 
for each genotype, which was run twice. 
 
Tissue content measured by HPLC. PFC and DStr tissue 
content of DA, dihydroxyphenylacetic acid (DOPAC), 
Homovanillic acid (HVA), noradrenaline (NA), 5-
hydroxytryptamine (5-HT) and 5-Hydroxyindoleacetic acid (5-
HIAA) was collected and analysed as previously described (23). 
  
Microdialysis in freely-moving animals. The functional 
state of DStr DA-transmission was assessed as previously 
described (24). Briefly, after collection of baseline DA 
dialysate fractions, extracellular DA levels were measured 
following reverse dialysis by application of the depolarizing 
agent veratridine (50 µM) (local 20 min pulse), and the 
dopamine/noradrenaline transporter uptake inhibitor 
nomifensine (50 µM) (local application during eight 
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fractions). PCP (2.5 + 2.5 mg/kg, s.c.) was administered 
systemically the following day to the same animals. 
Microdialysis measures were taken at AP +0.5, ML −1.7, DV −4.5 




 Loudness dependent auditory evoked potentials (LDAEPs). 
Auditory stimuli (white noise, 5 ms duration with 1 ms rise 
and fall) were presented to awake freely moving mice at 
different intensity levels (60, 70, 80, 90 and 100 dB) with a 
6 s inter-stimulus interval. 20 min EEG recordings were made 
during auditory stimulation. Grand average auditory evoked 
potentials from the auditory cortex (AuC) were constructed 
consisting of a 100 ms pre-stimulus baseline and a 900 ms 
post-stimulus interval. The peak N1- and P2-amplitudes were 
determined as the most negative deflection 10-25 ms post-
stimulus and the most positive deflection 22-65 ms post-
stimulus, respectively. Peak-to-peak N1/P2-amplitudes were 
determined at each intensity. Linear regression between peak-
to-peak N1/P2 amplitude and sound intensity was calculated and 
the LDAEP was determined as the mean slope of the linear 
regression. 
 
 Auditory induced brainstem response (ABR). ABRs were 
recorded with auditory stimulation to the left and right ears 
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of anaesthetised animals with hollow ear bars guiding sound 
waves to the external auditory meatus. Three subdermal 
electrodes were inserted; the active electrode was placed at 
the vertex, the reference electrode was placed at the ear 
being tested, and the ground electrode was placed near the 
opposite ear. ABRs were recorded during a series of click 
stimuli (duration: 50 µsec, rate: 20 Hz/s, intensity: 30-100 
dB in 5-dB steps) with 500 repeats per intensity level. 
Stimuli were presented to one ear, with the non-stimulated ear 
being blocked with an earplug. At each intensity ABRs were 
averaged and analysed within a 7 ms post-stimulus window. ABR 
thresholds were identified by visual inspection blinded to the 
genotype for both left and right ears and defined as the 
lowest intensity evoking a defl ction of the ABR wave. The ABR 
protocol used was modified from Fuchs et al. (2013).   
 
Low-frequency cortical oscillation (LFO). Medial 
prefrontal cortical (mPFC) LFO power was assessed at baseline 
and following systemic PCP treatment (10 mg/kg, s.c.) as 
previously described (26). Recordings were made at AP: + 2.1, 
ML: -0.2 to -0.4, DV: -1 to -2.5 mm from Bregma (25). 
 
mPFC GABAA receptor function. mPFC GABAA receptor (GABAAR) 
function was assessed by examining discharge rates of putative 
pyramidal neurons in control conditions and during local 
application of the GABAAR antagonist gabazine as previously 
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described (27). Recordings were made at AP: + 2.1, L: -0.2 to 
-0.4, DV: -1 to -2.5 mm from Bregma (25). 
 
Statistics 
Statistical analysis was performed by SigmaPlot (v11.2, 
Systat Software Inc.) or SPSS (v21.0, IBM Corp). Data were 
analysed by either 2-way analysis of variance (ANOVA), 2-way 
repeated measure (RM) ANOVA, or by t-test. Post-hoc test was 
conducted by the Holm-Sidak method. For the t-test Mann-
Whitney Rank Sum Test was used if normality (Shapiro-Wilk) or 
equal variance (Levene) test failed. 
No adjustments were made for multiple testing beyond the 
post-hoc tests. Data were visually inspected for outliers. No 
obvious outliers were identified and all data were included in 
the analysis. We only had few missing values. The missing 
values were handled by SigmaPlot using a general linear model. 
 
Results 
See Table 1 and Table A1 for summary of results.  
 
Generation of mice and basic phenotyping 
The Df(h22q11)/+ mouse line was generated by deletion of 
the human 22q11.2DS orthologous genomic region on mouse 
chromosome 16 (Figure 1a; Figure A1). Expression levels of 
deleted genes in cortical areas were examined by microarray 
analysis (Figure 1b). Except for Tssk1, Vpreb2, and Cdc45 
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expression of all detected genes in the deleted region were 
significantly reduced to roughly 50% of the expression in WT 
mice. Absolute expression levels assessed by RNAseq analysis 
of cortex in WT mice showed that Tssk1, Vpreb2, and Cdc45 
along with the undetected Tssk2 and Gsc2 genes were very lowly 
expressed suggesting that the apparent unchanged expression of 
these genes are due to very low signal-to-noise ratio in the 
microarray detection (data not shown). Expression of the 
flanking gene Car15 was also reduced by 50% in the 
Df(h22q11)/+ mouse, while expressions of other flanking genes 
were unaltered. Only around 40% of newborn pups were 
hemizygous indicating reduced conception or intrauterine 
survival (Df(h22q11)/+ fraction ≈ 0.40, p = 0.042) (Figure 
A3). In the following studies, hemizygous males were compared 
to WT male littermates. 
Overall, Df(22q11.2)/+  mice appeared healthy with 
grossly normal behaviour including pain sensitivity (hotplate: 
50-56°C), motor function (beam-walking, locomotor activity, 
rotarod) and anxiety response (bright open field, elevated 
plus maze) (Figure A3) and with normal brain weight and gross 
morphology (cortical layer composition, hippocampal 
structures, parvalbumin positive interneuron counts and myelin 
patterns) (Figure A3 and A4). 
 
Behaviour 
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Pre-pulse inhibition (PPI). PPI was significantly reduced 
in Df(h22q11)/+ mice (Fig 2a). Data were collapsed across 
prepulse intensities as there was no genotype × prepulse 
intensity (5, 10, 15dB) interaction. The PPI impairment was 
stable during development and consistently observed in 6 
independent cohorts of 6-21 weeks old animals. The impairment 
was resistant to treatment with haloperidol (Figure 2b) and 
clozapine (Figure 2c) representing typical and atypical 
antipsychotics, respectively. Clozapine impaired PPI in the WT 
mice at the highest dose tested (2 mg/kg). 
 
Acoustic startle response (ASR). Df(h22q11)/+ mice had 
increased ASR. The increased ASR was observed in 6 independent 
cohorts of 6-21 weeks old animals (Figure 2d). Haloperidol did 
not attenuate the increased ASR (Figure 2e). Clozapine 
decreased ASR in both WT and Df(h22q11)/+ mice. However, not 
genotype × treatment interaction effect was observed (Figure 
2f). 
 
PCP-induced hyperactivity. Df(h22q11)/+ mice showed 
hyper-reactivity to PCP induced locomotor activity in an age-
dependent manner. The hyper-reactivity was seen in 9-week old 
but not 7-week old mice (Figure 2g). 
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S-(+)-ketamine-induced hyperactivity. Df(h22q11)/+ mice 
at 26 weeks of age showed hyper-reactivity to ketamine induced 
locomotor activity (Figure 2h).  
 
Biochemistry 
Tissue content. Df(h22q11)/+ mice had increased levels of 
DOPAC in the PFC (Figure 3a) and DStr (Figure 3b) whereas the 
levels of DA, HVA, NA, 5-HT, and 5-HIAA were unaffected. 
 
Microdialysis in freely-moving animals. Df(h22q11)/+ and 
WT mice did not differ in baseline DStr DA, DOPAC, HVA, and 
glutamate levels (Figure 3c). Local administration of the 
sodium channel opener veratridine (Figure 3d) and the 
dopamine/noradrenaline reuptake inhibitor nomifensine (Figure 
3e) increased DA equally in Df(h22q11)/+ and WT mice. 
Similarly, PCP increased DStr DA equally in Df(h22q11)/+ and 
WT mice following both the first and second PCP challenge 
(Figure 3f). 
 
Western analyses. Df(h22q11)/+ showed decreased PFC NeuN 
and increased DStr GluR1 levels (Figure 3g). In a replication 
study using pooled samples from WT and Df(h22q11)/+ mice, 
respectively, the DStr GluR1 increase was confirmed while the 
PFC NeuN signal failed to replicate. There were no effects of 
genotype on levels of the 14 additional markers measured 
(Table 2). 
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Auditory induced brainstem response (ABR) threshold. 
Df(h22q11)/+ and WT mice did not differ in ABR threshold 
(Figure 4a). The ABR threshold did not exceed the previously 
defined hearing deficit criterion (55 dB SPL) (19). 
 
Loudness dependent auditory evoked potentials (LDAEP). 
The Df(h22q11)/+ mice showed increased LDAEPs in AuC (Figure 
4d-e). There was significant increase in P1/N1 and N1/P2 
amplitudes. The Df(h22q11)/+ mice showed increased LDAEP at 
higher sound intensities, the N1/P2 amplitudes were increased 
at 90 dB (p < 0.001) and 100 dB (p < 0.001). Similar results 
were generated for other cortical brain regions, with 
differences in N1 amplitude as the main contributing component 
(data not shown). There was no effect of genotype on latency 
at any sound intensity (data not shown). 
 
mPFC low frequency oscillations. There was no difference 
between Df(h22q11)/+ and WT mice on baseline or PCP-induced 
attenuation of cortical LFOs (Figure 4b). PCP decreased 
cortical LFOs. 
 
mPFC GABAAR function. There was no difference between 
Df(h22q11)/+ and WT mice on baseline or GABAAR antagonist 
induced elevation of pyramidal neuron spike frequency (Figure 
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In this paper we report on the generation and 
characterisation of a new 22q11DS mouse model with focus on 
assays relevant for the pathophysiology of schizophrenia. The 
Df(h22q11)/+ mice had age-independent and antipsychotic-
resistant gating deficits measured by PPI. They had increased 
acoustic startle response and increased amplitude of loudness-
dependent auditory evoked potentials. Also, the Df(h22q11)/+ 
mice exhibited increased NMDAr antagonist-induced locomotion, 
but in contrast to PPI, this effects was only observed post 
puberty. The 22q11.2 deletion resulted in increased DStr and 
PFC DOPAC levels as would be expected by the deletion of the 
COMT gene. Among other markers explored (figure 3 and table 2) 
we saw a reduction of DStr GluR1 expression. 
  PPI deficits and ASR changes have previously been 
reported in other 22q11DS mouse models (16-18).  We confirmed 
these findings in our model and further examined the age 
dependency, response to antipsychotic treatment and possible 
hearing confounds. We found that the PPI and ASR changes in 
Df(h22q11)/+  mice are robust (observed in 6 independent 
cohorts), present before puberty, and persisting across ages. 
This effect mirrors the reduced PPI found in human 22q11.2 
deletion carriers, which precede onset of puberty and 
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potential development of schizophrenia symptoms (13;14). 
Chronic middle ear infection and elevated click-response ABR 
threshold have been observed in the Df1/+ mouse model (19) 
raising the possibility that hearing loss at low intensities 
rather than sensorimotor gating deficits per se underlie the 
PPI deficits found in the 22q11DS mouse models. We addressed 
this by measuring ABR thresholds and found those to be 
unchanged in the Df(h22q11)/+ mice. This, together with the 
increased amplitude of auditory evoked potentials found in the 
LDAEP assay indicate that hearing is not reduced in the 
Df(h22q11)/+ mouse. Thus, the decrease in sensorimotor gating 
observed in the Df(h22q11)/+ mouse is not caused by hearing 
loss. The contrasting ABR findings between the Df(h22q11)/+ 
and Df1/+ mouse model (19) may be due to differences in strain 
or environmental conditions affecting the risk of ear 
infection. 
  The PPI and ASR impairments were resistant to 
antipsychotic treatment (haloperidol and clozapine), which is 
in overall agreement with the effect of these drugs in the 
clinical setting. In schizophrenia patients, classical 
antipsychotics working through D2/D3 receptor blockade reduce 
the psychotic symptoms without affecting PPI deficits (28;29). 
The findings for the new generation of antipsychotics with 
multi-receptor profiles are more mixed (28;30;31) and a cross-
sectional study by Kumari (32) provided indirect evidence for 
clozapine being superior to haloperidol on PPI deficits in 
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schizophrenia patients, which is not reflected by the present 
data from the Df(h22q11)/+ mice.  
Similar to the Df1/+ mouse (33), we found that 
Df(h22q11)/+ mice displayed increased locomotor activity in 
response to the NMDAr antagonists PCP and Ketamine. 
Interestingly, we further found that the effect was age-
dependent and only observed after puberty (9- but not 7-week 
old animals). As schizophrenia is characterised by onset of 
overt symptoms during or after puberty (34) and glutamatergic 
dysfunctions (35;36), our data suggest that the Df(h22q11)/+ 
mouse may model aberrant NMDAr-related neurodevelopment 
trajectories associated with the disorder. The pre-pubertal 
and age-independent PPI deficits found in the Df(h22q11)/+ 
mice suggest that these sensorimotor gating deficits are due 
to biological perturbation other than what drives the NMDAr 
antagonist phenotype. 
Biochemical assays revealed that the Df(h22q11)/+ mice 
had elevated PFC and DStr tissue content of the DA metabolite 
DOPAC. This phenotype may be explained by the 
haploinsufficiency for COMT, which catalyses the demethylation 
of DA. The role of COMT is well established in low-DAT density 
brain regions such as the PFC (37;38) whereas there are 
contrasting findings in striatum (39;40). The present data 
also support a role of COMT in striatal DA function. Despite 
the reduced expression of COMT and consequent increase in 
DOPAC we saw no changes in tissue content of DA and HVA, NA or 
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5-HT. The Df(h22q11)/+ mice also showed normal DStr DA release 
following PCP administration and local application of 
veratridine or nomifensine. DA release is involved in, but 
temporally dissociated from, NMDA antagonist-induced locomotor 
activity (41). The observed hypersensitivity to NMDAr blockade 
is likely not caused by hypersensitivity of the DA system in 
the Df(h22q11)/+ mice as release of DA is unchanged. This is 
further supported by the lack of locomotor hyper-responsivity 
to amphetamine in these mice (unpublished data). GluR1 was the 
only glutamatergic related marker (GluR2, NR2A, or NR2B, 
VGluT1) explored showing differential expression and we did 
not observe any changes in GABA related markers (GABAA α1, 
KCC2, VGAT, GAD 65/67). Furthermore, PFC GABAergic-
glutamatergic interaction measured as GABAAR antagonism 
induced pyramidal cell discharge rates was not affected, and 
measures of PCP-induced attenuation of low frequency cortical 
oscillations showed preserved function of cortical neuronal 
networks in the Df(h22q11)/+ mice. Thus, expression of most 
receptors for the major transmitters is not altered and the 
mechanism responsible for increased behavioural responsivity 
to NMDAr blockade is unknown, which should be investigated 
further in future studies. 
In line with the increased ASR, the amplitude of auditory 
evoked potentials were increased in Df(h22q11)/+ mice. The 
amplitude of auditory evoked potentials is decreased in 
schizophrenia (42) whereas mixed results have been found for 
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LDAEP. In some studies LDAEP have been found to be reduced in 
schizophrenia patients but these studies were not designed to 
account for difference in symptomatology (43;44). In a recent 
study by Wyss et al. (45) increased LDAEP was found in 
schizophrenia patients with predominant negative symptoms, 
which interestingly is also prominent in the symptomatology of 
patients with the 22q11.2DS (46-48) together with increased 
auditory event related potentials (49). Negative symptoms is 
also prominent in autism another disorder associated with the 
22q11.2DS and increased amplitude of auditory evoked 
potentials have been reported in autism related syndromes like 
fragile X (50) and in animal models of autism (51;52). We have 
not assessed behavioural functions related to negative 
symptomatology in the present paper. However, reports of a 
reduced progressive ratio response in Df(16)A+/- mice (53) 
supports negative symptom-like behaviour in these mice (54). 
Hence the Df(h22q11)/+ mouse may also prove to be a useful 




Genetic mouse models provide insight into the consequence 
of the mutation in a specific genetic and environmental 
context. More marked changes might have been anticipated from 
introducing a high risk genetic variant comprising more than 
25 genes into the mouse. However, it is important to keep in 
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mind that the 22q11.2 micro-deletion has incomplete penetrance 
in humans, expression and severity of disease depends on the 
complete genetic makeup (20) in concert with environmental 
influences. Thus, the Df(h22q11)/+ mouse is more appropriately 
thought of as a liability model rather than a disease model. 
This is in line with our previous findings that CNVs 
conferring high risk of mental disorders significantly affect 
structure and function of the brain in healthy human carriers 
(55). In order to obtain more marked phenotypes reflecting the 
severe conditions related to 22q11.2DS it is suggested to 
combine the Df(h22q11)/+ mouse with environmental stressors as 
used by Giovanoli et al. (56), which may unmask latent 
psychopathology. Giovanoli and colleagues showed how 
unpredictable stress during pub rty resulted in PPI deficits 
and increased sensitivity to amphetamine and MK-801 in mice 
exposed to prenatal immune activation. In contrast, Harper et 
al showed how reduced social interaction in Sept5 KO mice, one 
of the 22q11.2 genes, could be rescued by reducing the level 
of stress (21), clearly demonstrating interaction between 
genotype and environment.  
Sex differences in the behaviour of children with 
22q11.2DS have been reported (57). Thus, it is highly relevant 
to explore sex differences in the mouse. In the present paper 
only male mice were included. Pilot studies conducted in our 
lab comparing male and female Df(h22q11)/+ mice did not reveal 
differences in motor function, seizure threshold, anxiety, or 
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amphetamine-induced locomotion. The studies have to be 
repeated and extended before firm conclusions can be made. 
We did only observe few changes in protein expression. 
Additional synaptic fractionation might increase the 
resolution of the analysis, particularly with respect to 
synaptic proteins. However, the method used allowed us to 
investigate both synaptic (e.g. PSD95) and astrocytic markers 
(e.g. GFAP).   
 
Conclusion 
Here we show how the Df(h22q11)/+ mouse model reflects 
different developmental aspects of the 22q11.2DS and 
schizophrenia including changes in information processing and 
NMDAr antagonist responsiveness. Furthermore, the present 
findings extends previous reports on other 22q11.2DS mouse 
models by showing age-independent and antipsychotic-resistant 
gating deficits that are not confounded by reduced hearing. 
This model will be a valuable tool for further understanding 
the aetiology of schizophrenia and other psychiatric disorders 
with the ultimate goal of developing novel and improved drugs. 
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Phenotype Measure      
PPI and 
startle 
Pre-pulse inhibition      
    Pre-puberty ↓ - - - - 
    Post-puberty ↓ ↓(16) ↓(14) ↓(15) ↑(24) 
    Clozapine or haloperidol  X - - - - 
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 Acoustic startle       
    Pre-puberty ↑ - - - - 
    Post-puberty ↑ X(15) ↑(14) ↑(15) X(24) 
    Clozapine or haloperidol 
challenges 
X - - - - 
Stimulant 
LMA 
PCP      
    Pre-puberty X - - - - 
    Post-puberty ↑ - - - - 
 Ketamine (post-puberty) ↑ - - - - 
Electrophysi
ology 
Prefrontal spike frequency      
    Baseline X - - - - 
    Gabazine Challenge X - - - - 
 Cortical low frequency      
Page 42 of 83
For Peer Review Only
































































    Baseline X - - - - 
    PCP challenge X - - - - 
 LDAEP ↑ - - - - 
 ABR x - - ↓(17) - 
Biochemistry HPLC (PFC and DStr)      
    DOPAC ↑ - - - - 
    DA, 5-HT, NA, 5-HIAA, HVA x - - - - 
 DStr microdialysis      
    Baseline DA, DOPAC, Glu, 
HVA 
X - - - - 
    Veratridine, nomifensine, 
PCP challenge 
X - - - - 
 Western analysis (PFC, DStr, 
Hipp) 
     
    Synaptic (PSD-95, SYP, X - - - - 
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Syn1, Drebrin, geophysin) 
    Cell type (NeuN, GFAP) X - - - - 
    GABA (GABAAα1, KCC2, VGAT, 
GAD65/67) 
X - - - - 
    Glutamate (GluR2, NR2A, 
NR2B, VGluT1) 
X - - - - 
    DStr GluR1 ↑ - - - - 
Table 1. Summary of results for Df(h22q11)/+ and other 22q11.2DS mouse models. ↓ 
decreased, ↑ increased, x no effect, - no data.  LMA = Locomotor activity; PFC = 
prefrontal cortex; DStr = dorsal striatum; Hipp = hippocampus; LDAEP = loudness 
dependence auditory evoked potentials; ABR = auditory induced brainstem response. 
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Type Marker Function PFC DStr Hipp 
Synaptic PSD-95 Scaffolding protein 
at excitatory post 
synaptic densities 
x x x 
 Synaptophysin Synaptic vesicle 
protein 
x x x 
 Synapsin 1 Phosphoprotein 
associated with 
surface of synaptic 
vesicles 
x x x 
 Drebrin Actin-binding 
protein involved in 
neuronal /spine 
growth 
x x x 
 Gephyrin Scaffolding protein 
in inhibitory 
synaptic densities 
x x x 
Cell type NeuN Nuclear antigen. 
Biomarker of 
neurons 
(↓) x x 
 GFAP Intermediate 
filament in 
astrocytes 
x x x 
Glutamate GluR1 AMPA receptor x ↑ x 
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 GluR2 AMPA receptor 
subunit 
x x x 
 NR2A NMDA receptor 
subunit 
x x x 
 NR2B NMDA receptor 
subunit 
x x x 
 VGluT1 Vesicular glutamate 
transporter at 
vesicle  membrane 
x x x 
GABA GABAA α1 GABAA receptor 
subunit 
x x x 
 KCC2 Neuron specific 
potassium-chloride 
transporter 
x x x 
 VGAT Vesicular GABA 
transporter found 
on synaptic vesicle 
membrane 
x x x 
 GAD 65/6 Enzymes catalysing 
decarboxylation of 
glutamate to GABA 
x x x 
Table 2. Protein level in Df(h22q11)/+ and WT littermates ↓ 
decreased, ↑ increased, x no effect. () did not replicate. PFC 
= prefrontal cortex, DStr = dorsal striatum, Hipp = 
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Figure 1. Construct similarities in Df(h22q11)/+ and human 
deletion carriers. (a) Overview of the deleted region (shaded) 
in human (22q11.2) and the corresponding orthologous region in 
mouse (16qA3). The maps are based on human library GRCh38/hg38 
and mouse library GRCm38/mm10 from the UCSC database. Only 
annotated RefSeq sequences are shown for clarity. (b) Median 
normalized microarray analysis of relative cortical expression 
of gene products from deleted segment in Df(h22q11)/+ compared 
with WT littermates. Asterisk denote significant difference 
between WT and Df(h22q11)/+ (***p< 0.001). N.D.: not detected. 
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Figure 2. Behavioural characterisation of Df(h22q11)/+ and WT 
littermates. (a) Pre-pulse inhibition (PPI). Df(h22q11)/+ mice 
showed decreased PPI. The PPI deficit was reproduced in 6 
independent cohorts 6-21 weeks of age (n = 12-24/group) (t-test 
was conducted for each week; W6: t45 = 3.6, p<0.001; W9: t30 = 
4.8, p<0.001; W15: t29 = 6.3, p<0.001; W17: t22 = 3.9, p<0.001; 
W19: t22 = 4.9, p<0.001; W21: t22 = 6.4, p<0.001). (b) PPI – 
effect of haloperidol. Haloperidol did not rescue the PPI 
deficit (n = 12/group) (2-way ANOVA; genotype: F1,94 = 69.1, p < 
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0.001; dose: F3,94 = 1.02, p = 0.38; genotype×dose: F3,94 = 0.59, 
p = 0.63). (c) PPI – effect of clozapine. Clozapine did not 
rescue the PPI deficit (n=13/group) (2-way ANOVA; genotype: 
F1,87 = 46.3, p < 0.001; dose: F3,87 = 4.87, p = 0.004; 
genotype×dose: F3,87 = 6.14, p < 0.001). (d) Acoustic startle 
response (ASR). Df(h22q11)/+ mice had increased ASR. The 
increased ASR was found in 6 independent cohorts 6-21 weeks of 
age (n = 12-24/group) (t-test was conducted for each week; W6: 
T = 418, p = 0.004; W9: T = 204, p = 0.025; W15: T = 340, 
p<0.001; W17: T = 79, p<0.001; W19: t22 = -4.51, p<0.001; W21: T 
= 101, p = 0.005). (e) ASR – effect of haloperidol. Haloperidol 
did not attenuate the increased ASR (n = 12/group) (2-way 
ANOVA; genotype: F1,94 = 88.5, p < 0.001; dose: F3,94 = 0.060, p 
= 0.98; genotype×dose: F3,94 = 0.13, p = 0.95). (f) ASR – effect 
of clozapine. Clozapine did not attenuate the increased ASR (n 
= 13/group) (2-way ANOVA; genotype: F1,87 = 83.1, p < 0.001; 
dose: F3,87 = 9.35, p < 0.001; genotype×dose: F3,87 = 1.49, p = 
0.22). (g) PCP-induced locomotor activity. Age-dependent 
hypersensitivity to PCP-induced locomotion in Df(h22q11)/+ mice 
(n = 12/group) (t-test was conducted for each week; W7: t22 = 
1.10, p = 0.28 at 2.5 mg/kg; t22 = -0.68, p = 0.50 at 5.0 mg/kg; 
W9: T = 90, p = 0.011 for vehicle; T = 187, p = 0.035 at 1.25 
mg/kg; t22 = -2.33, p = 0.029 at 2.5 mg/kg; t22 = -0.91, p = 0.37 
at 5.0 mg/kg).  (h) Ketamine-induced locomotion. 
Hypersensitivity to ketamine induced locomotion in Df(h22q11)/+ 
mice (n = 13-16/group) (2-way ANOVA; genotype: F1,54 = 0.23.1, p 
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= 0.64; dose: F11,54 = 25.6, p < 0.001; genotype×dose: F1,54 = 
5.95, p = 0.018; post hoc within ketamine 10 mg/kg t = 2.05, p 
= 0.044). Data are presented as mean + SEM. Asterisk denote 
significant differences between WT and Df(h22q11)/+ (*p < 0.05, 
**p< 0.01, ***p< 0.001). # denote significant difference 
within genotype relative to vehicle (#p < 0.05, ###p< 0.001). 
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Figure 3. Biochemical measures in Df(h22q11)/+ and WT 
littermates. (a) PFC whole tissue content. The level of DOPAC 
was increased in Df(h22q11)/+ mice (n = 8-10/group)  (t-test 
was conducted for each analyte; DA: t16 = -0.22, p = 0.83; 
DOPAC: t16 = -3.85, p = 0.001; HVA: t16 = -0.48, p = 0.64; NA: T 
= 81, p = 0.69; 5-HT: T = 83, p = 0.56; 5-HIAA: t16 = -0.93, p = 
0.38 (b) DStr whole tissue content.  The level of DOPAC was 
increased in Df(h22q11)/+ mice (n = 9-15/group)  (t-test was 
conducted for each analyte; DA: t27 = 0.45, p = 0.66; DOPAC: T = 
156, p = 0.020; HVA: T = 215, p = 0.84; NA:T = 238, p = 0.85; 
5-HT: t28 = 0.91, p = 0.37; 5-HIAA: T = 198, p = 0.16. (c) 
Microdialysis - DStr baseline. No genotype effect (n = 14-
15/group) (t-test was conducted for each analyte; DA: T = 203, 
p = 0.52; DOPAC: t27 = -0.69, p = 0.50; HVA: t19 = 0.98, p = 
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0.34; Glu:T = 191, p = 0.58). (d) Effect of local veratridine 
application on DStr DA release. Veratridine increased DStr DA 
similarly in WT and Df(h22q11)/+ mice (n = 14/group) (2-way RM 
ANOVA; genotype: F1,26 = 0.24, p = 0.63; time: F8,208 = 18.8, p < 
0.001; genotype×time: F8,208 = 1.35, p = 0.22). (e) Effect of 
local nomifensine application on DStr DA release. Nomifensine 
increased DStr DA similarly in WT and Df(h22q11)/+ mice (n = 
14/group) (2-way RM ANOVA; genotype: F1,26 = 0.12, p = 0.74; 
time: F10,260 = 25.5, p < 0.001; genotype×time: F10,260 = 0.79, p 
= 0.64). (f) Effect of PCP on DStr DA release. PCP increased 
DStr DA similarly in WT and Df(h22q11)/+ mice (n = 14/group) 
following both the first (genotype: F1,28 = 0.003, p = 0.958; 
genotype×time: F4,112 = 0.742, p = 0.565) and second PCP 
challenge (genotype: F1,28 = 1.632, p = 0.212; genotype×time: 
F5,140 = 0.432, p = 0.826).(g) Western analyses. The initial 
analysis show decreased PFC NeuN (t20 = 2.92, p = 0.009) and 
increased DStr GluR1 expression (t20 = 2.99, p = 0.007) in 
Df(h22q11)/+ mice (n = 11/group). However, the NeuN decrease 
failed to replicate when samples were pooled. Data are 
presented as mean + SEM or mean ± SEM. Asterisk denote 
significant differences between WT and Df(h22q11)/+ (*p < 0.05, 
**p< 0.01). DA (dopamine); DOPAC (3,4-Dihydroxyphenylacetic 
acid); HVA (homovanillic acid); NA (norepinephrine); 5-HT (5-
hydroxytryptamine); 5-HIAA (5-Hydroxyindoleacetic acid). VTD 
(veratridine); UPO (unpooled); POR (pooled replication); DStr 
(dorsal striatum).  
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Figure 4. Electrophysiological measures in Df(h22q11)/+ and WT 
littermates. (a) Auditory brain stem response (ABR). The 
hearing in the Df(h22q11)/+ mice was not different from WT (n = 
13/group) (2-way RM ANOVA; genotype: F1,24 = 1.649, p = 0.211; 
ear: F1,24 = 0.331, p = 0.571; ear×genotype: F1,24 = 3.570, p = 
0.071). (b) PCP induced attenuation of cortical low frequency 
oscillations (LFO). PCP caused similar decrease of cortical 
LFOs in WT and Df(h22q11)/+ mice (n = 9/group) (2-way ANOVA; 
genotype: F1,48 = 2.40, p = 0.13; condition: F2,48 = 3.44, p = 
0.040; genotype×condition: F2,24 = 0.013, p = 0.99). (c) 
Gabazine-induced elevation of mPFC pyramidal spike frequency. 
Gabazine caused similar increase in pyramidal spike frequencie 
in WT and Df(h22q11)/+ mice (n = 14/group) (2-way ANOVA; 
genotype: F1,87 = 1.21, p = 0.28; treatment: F1,87 = 20.9, p < 
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0.001; genotype×treatment: F1,87 = 1.12, p = 0.29). (d) LDAEP 
waveforms. Grand average LDAEP waveforms from AuC in WT and 
Df(h22q11)/+ mice (n = 22-23/group) (2-way RM ANOVA; 
P1/N1:genotype: F1,43 = 22.6, p < 0.001; intensity: F4,43 = 
75.5, p < 0.001; genotype×intensity: F4,43 = 13.7, p < 0.001; 
N1/P2: genotype: F1,43 = 9.89, p = 0.003; intensity: F4,43 = 
156.4, p < 0.001; genotype×intensity: F4,43 = 9.76, p < 0.001). 
(e) LDAEP slope. Collapsed LDAEP slopes for Df(h22q11)/+ and WT 
mice (n=22-23/group) (t-test; t43 = -3.896, p < 0.001). Data are 
presented as mean + SEM or mean ± SEM. Asterisks denote 
significant differences (*p < 0.05, ***p< 0.001).  
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Generation of the Df(h22q11)/+ mouse (Figure A1)  
The mouse construct was generated using two targeting 
vectors. The first vector introduced a loxP site with an FRT-
flanked Neomycin resistance cassette upstream of exon 9 in the 
Dgcr2 gene. The second vector introduced a loxP site with an F3-
flanked Puromycin resistance cassette downstream of exon 24 in 
the Hira gene. Both constructs also contained a thymidine kinase 
gene for negative selection. Targeted sequences were generated 
using BAC clones from the C57BL/6J RPCI-23 BAC library. First, 
linearized Dgcr2-targeting vectors were electroporated into the 
TaconicArtemis C57BL/6N Tac embryonic stem cell (ESC) line. 
Homologous recombinant clones were isolated by positive (G418 
resistance) and negative (Gancyclovir resistance) selection. The 
genetic construct was validated by southern blotting to confirm a 
single integration on only one chromosome. Secondly, selected ESC 
lines were electroporated with linearized Hira-targeting vector. 
Homologous recombinant clones were isolated using positive 
(puromycin resistance) and negative (Gancyclovir resistance) 
selection. Again, the genetic construct was validated by southern 
blotting to confirm a single integration on only one chromosome. 
Thirdly, double targeted ESC lines were electroporated with a 
cre-recombinase expressing construct to facilitate in vitro Cre-
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mediated recombination in ESC clones with the two loxP sites 
inserted on the same chromosome. The ESCs hemizygotic for the 
1.13Mb deletion were identified by southern blotting and 
polymerase chain reaction (PCR) analysis. The final construct had 
section 17,840,564 – 18,970,580 (a 1,129,815 basepair deletion) 
exchanged with a 101 basepair sequence containing a loxP site on 
chromosome 16 as mapped to reference sequence NC_000082.6 from 
the GRCm38/mm10 library. Finally, selected ESCs were 
microinjected into blastocysts isolated from impregnated BALB/c 
females and transferred to pseudopregnant NMRI females. Chimeric 
male pups were selected by coat colour and mated with WT C57BL/6N 
females and a chimera with germline transmission was selected for 
expansion breeding. Genotypes were controlled during breeding by 
PCR on tail biopsies.  
 
Confirmation of the transcriptional levels (Figure 1b) 
To confirm the transcriptional changes of the genetic 
construct, tissue was isolated from the frontal part of the 
cortex by hand dissection and shipped for RNA extraction and 
microarray analysis at Miltenyi Biotec, Germany. In brief, RNA 
was isolated using standard RNA extraction protocols (Trizol) and 
quality-checked via the Agilent 2100 Bioanalyzer platform 
(Agilent Technologies, RNA integrity values were between 7.2 and 
9.1). 100ng of each sample was used for a linear T7-based 
amplification step to produce Cy3-labeled cRNA using the Agilent 
Low Input Quick Amp Labeling Kit (Agilent Technologies) according 
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to manufacturer. 600ng of Cy3-labeled fragmented cRNA was then 
hybridized to Agilent 8x60K Whole Mouse Genome Oligo Microarrays 
overnight (17 hours, 65°C) according to the Agilent 60-mer oligo 
microarray processing protocol using the Agilent Gene Expression 
Hybridization Kit (Agilent Technologies). Finally, the 
microarrays were washed and read using Agilent’s Microarray 
Scanner System. Scanned images were processed using the Agilent 
Feature Extraction Software (FES) which determines feature 
intensities (including background subtraction), rejects outliers 
and calculates statistical confidences. Normalized signal 
intensities were obtained by dividing each value by the median 
value of each array. Genes close to the deleted region were 
included for detection of possible effects on bordering genes. 
The number of genes upstream and downstream of the deleted region 
was increased until transcripts could be detected in WT cortex 
above background levels (based on FES). Significance levels are 
based on two-tailed t-test with Welsh correction. Data presented 
as expression in the Df(h22q11)/+ relative to WT. 
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Supplementary Figure A1. Generation of Df(h22q11) mice. A) WT 
Dgcr2 loci and the corresponding targeted loci following 
introduction of a lox P site and Neomycin resistance gene. B). WT 
Hira loci and the corresponding targeted loci following 
introduction of a lox P site and Puromycin resistance gene. C) 
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Cre-induced recombination between loxP sites in cis leads to 
around 1.13-Mb deficiency, leaving only a single Lox P site. 
Deletion specific oligonucleotides used for PCR analysis are 
indicated around the Lox P sites D) Due to the recombination of 
the loxP sites, a diagnostic 150-bp PCR product can be detected 
in Df(h22q11) mice. The 103 bp PCR product is internal control to 




For the age at the start of each experiment and the distribution 
of the 27 cohorts of Df(h22q11)/+ and WT littermates used for the 
studies please refer to Figure A2 below.  
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Supplementary Figure A2.Cohort 1 was used for PFC microarray 
analyses (WT N = 12, TG N = 5). Cohort 2 was used for whole 
tissue content analyses (PFC: WT N = 8, TG N = 10; DStr: WT N = 
14/15, TG N = 15). Cohort 3 was used for microdialysis 
experiments (WT N = 14, TG N = 14). Cohort 4 was used for LDAEP 
analyses (WT N = 22; TG N = 23). Cohort 5 was used for ketamine-
induced hyperactivity (WT N = 13, TG N = 16). Cohort 6 (WT N = 
14, TG N = 14) was used for the intra-mPFC gabazine experiment. 
Cohort 7 (WT N = 9; TG N = 9) was used for the cortical LFO 
experiment. Cohort 8 was used for western analyses (WT N = 11; TG 
N = 11). Cohort 9 was used for hot plate (WT N = 12, TG N = 12). 
Cohort 10 was used for beam walking (WT N = 16; TG N = 16). 
Cohort 11 was used for basal LMA (WT N = 48; TG N = 47). Cohort 
12 was used for brain weight (WT N = 9; TG N = 9). Cohort 13 was 
used for auditory brainstem response analyses (ABR; WT N = 13; TG 
N = 13). Cohort 14 was used for gross histological and 
immunoreactivity studies (WT N = 6; TG N = 6). Cohort 15 and 
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Cohort 16 (WT Ns = 12; TG Ns = 12) was used for PCP-induced 
hyperactivity. Cohort 17 was used for elevated plus maze (WT N = 
12; TG N = 12). Cohort 18 (WT N = 23; TG N = 24), Cohort 19 (WT N 
= 16; TG N = 16), Cohort 20 (WT N = 16; TG N = 15), Cohort 21, 
Cohort 22, and Cohort 23 (WT Ns = 12; TG Ns = 12) were used for 
PPI. Cohort 24 (WT N = 13; TG N = 13) and Cohort 25 (WT N = 12; 
TG N = 12) were used for haloperidol- and clozapine-challenged 
PPI experiments. Cohort 26 (WT N = 16; TG N = 16) was used for 
the bright open field. Cohort 27 (WT N = 10; TG N = 10) was used 
for the rotarod experiment. CSIC = Consejo Superior de 
Investigaciones Científicas, Barcelona. 
 
 
Beam-walking (Figure A3i) 
The day before testing, all mice were individually trained 
to traverse a narrow beam (16 mm wide 75 cm long) at a height of 
30 cm to reach a dark enclosure. The beam walking test was 
performed in daylight the following day, using a thinner test 
beam (8 mm wide). Each animal was observed for foot slips, falls 
and time to cross the beam. 
 
Rotarod (Figure A3e) 
The rotarod test was performed using a Rotamex 4/8 (Columbus 
Instruments, 950N. Hague Avenue, Columbus, Ohio 43204 USA), 
equipped with 2x4 lanes and 75 mm rods. A paradigm accelerating 
from 4 - 40 rpm within 5 min, and a detection delay set to 0 
seconds, was used. Each mouse was tested in the paradigm 3 times 
/ day with a 20 min break between each trial for 4 consecutive 
days. The Columbus instruments special designed software 
automatically calculated the accumulated time-on-the-rod. Both 
maximum latency (best performance of the day) and average latency 
each day to fall off the rotating rod was scored for each 
session. 
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Locomotor activity (Figure A3d) 
Mice were placed individually in macrolon locomotor activity 
cages (20 cm × 35 cm × 18 cm) to habituate for 60 min and basal 
locomotor activity was measured. The locomotor activity cages 
were equipped with 5 × 8 infrared light sources and photocells. 
The light beams crossed the cage 1.8 cm above the bottom of the 
cage. To avoid stationary movement artefacts, two consecutive 
crossings of adjacent infrared light beams were recorded as a 
motility count. Registration and timing of locomotor activity was 
fully automated (custom-designed hardware and software by 
Ellegaard Systems A/S, Faaborg, Denmark). 
 
NMDAr antagonist induced activity (Figure 3g-h) 
PCP study. Mice were placed individually in macrolon 
locomotor activity cages (20 cm × 35 cm × 18 cm) to habituate for 
60 min. After the habituation period, vehicle or PCP (1.25, 2.5 
or 5.0 mg/kg, s.c., 10 ml/kg) was administered and locomotor 
activity was recorded for an additional 60 min. The locomotor 
activity cages were equipped with 5 × 8 infrared light sources 
and photocells. The light beams crossed the cage 1.8 cm above the 
bottom of the cage. To avoid stationary movement artefacts, two 
consecutive crossings of adjacent infrared light beams were 
recorded as a motility count. Registration and timing of 
locomotor activity was fully automated (custom-designed hardware 
and software by Ellegaard Systems A/S, Faaborg, Denmark). 
Ketamine study. The study was conducted in complete dark 
test rooms, using clear Perspex boxes (40×40×30 cm) which were 
placed on infrared fields (100×100 cm), four boxes per field. 
Locomotor activity was monitored using overhead infrared cameras 
(Sanyo VCV-3412P, TrackSys Ltd, UK), that fed into a PC running 
the image analysis application Ethovision v2.2 (Noldus, NL). Mice 
were assigned to treatment groups/sequence using a 
pseudorandomised block method where treatments were balanced 
across the time of day, the test room and the week of testing. On 
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each test day, mice were placed individually into the test boxes 
to habituate for 60 min. After the habituation period, vehicle or 
S-(+)-ketamine (10 mg/kg, s.c., 10 ml/kg) was administered and 
locomotor activity was recorded for an additional 60 min. 
 
Hotplate (Figure A3f) 
The test was performed using Ugo Basile 7280 Hotplate 
system, (Ugo Basile, Biological Research Apparatus, 21025 Comerio 
VA Italy). Mice were individually placed in a glass cylinder on 
the heating plate with a fixed temperature. Latency time to 
lifting one limb or jumping was measured. Each mouse was tested 3 
times at increasing temperature levels 50, 53 and 56 ºC with 30 
min break between each test. Average latency time was calculated 
for each temperature level. 
 
Bright open field (Figure A3h) 
Individual mice were placed in a bright illuminated (120 
lux) circular open field (74 cm diameter). Activity was measured 
for one hour by a camera installed above the arena. Movement and 
position was automatically video tracked and quantified into 3 
predefined zones; Center (25 cm diameter), middle (12.5 cm band) 
and outer (12.5 cm band) using the Ethovision 7.0 software 
(Noldus Information Technologies, Wageningen, the Netherlands).  
 
Elevated plus maze (Figure A3g) 
The elevated plus maze setup, consisted of a grey plus-
shaped maze with 2 open arms and 2 arms with side walls, also 
referred to as closed arms (arm dimension 17x8 cm). The maze was 
elevated 40cm above the floor, with an infrared camera installed 
above. The test was performed in darkness (2-5 lux). 
Mice were individually placed in the centre of the maze and 
allowed to explore for 5 min. Movement and position was 
automatically video tracked and quantified into time spent on 
open vs. closed arms and number of entries into zones (defined by 
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head and forelimbs entered into the zone), using the Ethovision 
7.0 software (Noldus Information Technologies, Wageningen, the 
Netherlands). 
 
Prepulse inhibition (PPI) (Figure 2a-f) 
PPI testing was performed using the SM100 Startle Monitor 
System (Kinder Scientific, USA), consisting of 8 sound-attenuated 
startle chambers and StartleMonitor software (Kinder Scientific, 
USA). Animals were placed in an adjustable Plexiglas holder, 
providing limited movement but not restraint, positioned directly 
above a sensing platform registering the animals startle 
response. Each test session consisted of a 5 min acclimatization 
period with only background white noise (62 dB), followed by a 
brief habituation setting where 32 regularly occurring startle 
pulses of 105 dB (intertrial interval (ITI): 10 s) were presented 
to the animals to maximize habituation prior to the PPI part of 
the session. Animals were then subjected to 5 types of trials 
presented 12 times each in a balanced manner: pulse alone, 
prepulse + pulse (5, 10 or 15 dB above background), or highest 
prepulse intensity (77 dB) alone. ITI varied between 9 and 21 s 
(average ITI 15 s) and inter-stimulus interval (ISI) was set to 
100 ms with a prepulse length of 20 ms.  Each PPI session ended 
with 8 startle pulses of 105 dB to estimate habituation across 
PPI trials. The full PPI test lasted about 28 min. PPI was 
calculated as % PPI for each prepulse intensity as: 100 − 
((prepulse + pulse/pulse alone) × 100), i.e. a lower percentage 
score indicates a decrease in PPI. Startle magnitude was 




Loudness dependence auditory evoked potentials (Figure 4) 
Surgical procedures. Epidural screw electrodes (Plastic One, 
Virginia) were placed according to coordinates from Franklin and 
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Paxinos(1) at the following positions relative to bregma in the 
auditory cortex (AP: -2.92 mm, ML:  -4.25 mm), frontal cortex 
(AP: +2.8, ML: -0.5 mm), parietal cortex corresponding to the 
vertex (AP: -2.0, ML: -2.0 mm), reference (AP: -6.0, ML: +2.0 mm) 
and ground (AP: -2.0, ML: +2.5 mm). A teflon-coated stainless 
steel depth electrode (0.125 mm, Plastic One, Virginia) was 
placed in the hippocampus (CA1) at (AP: -3.16, ML: -3.2, DV: -1.4 
mm to dura). The location of the hippocampal depth electrode was 
verified by histological inspection. Electrodes were connected to 
a 6-channel pedestal (Plastic One, Virginia), which was fixated 
to the skull with dental cement (GC Fuji PLUS Capsule, GC 
Corporation, Japan). Post-surgery, mice were housed individually 
and allowed minimum of two weeks recovery including five days of 
handling and one day of habituation to the test environment 
without (1 h) and with auditory stimulation (2h). In the post-
surgical period, the circadian rhythm of the mice was reversed 
(12 hours of light starting at 6 pm) to allow 
electrophysiological experiment to be performed during the dark 
phase (active phase). On test days, mice were habituated to the 
test environment for 2 h prior to auditory testing. 
Electroencephalography (EEG) recordings. EEG was recorded in 
WT and Df(h22q11)/+ mice during the dark phase by connecting a 
custom made 6-channel cable attached to a 10-channel commutator 
(Dragonfly, USA) allowing the mice to move freely. EEG data was 
digitalised and collected at a sampling rate of 1000Hz 
(Power1401, Cambridge Electronic Design, Cambridge, UK) and 
amplified with gain x1000 and band-pass filtered using hardware 
filter at 1.0-300 Hz with an additional notch filter to remove 50 
Hz noise (BrownLee, model 440, USA). Auditory stimuli generation 
and data analyses were done using the Spike 2 software package 
(v. 7.07; Cambridge Electronic Design, Cambridge, UK). Auditory 
stimulus was presented via two speakers in the side of the 
housing cages in custom made sounds attenuated faraday steel 
boxes. The sounds intensity was controlled by a custom made sound 
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attenuator (Ellegaard Systems, Denmark) and an amplifier (Tony 
Lee DJ201, JCLEON International Electronic, China). 
 
Auditory brainstem response (Figure 4) 
ABR measures evoked by click-stimuli from left and right 
ears were recorded in a sound-attenuating faraday cage. Mice were 
anaesthetised with ketamine/xylazine (0.1 ml/10 g of 10 mg 
ketamine/10 g and 0.1 mg xylazine/10 g; 10 ml/kg, i.p.) and 
placed in a stereotaxic frame with hollow ear bars guiding sound 
waves to the external auditory meatus. A heating pad maintained 
body temperature was during recordings.  Subdermal needle 
electrodes (HUSH™ Shielded Electrode Cable, 3x0.7 mm female, 2 m; 
Dantec Disposable Scalp Needle Electrodes, 10 x 0.30 mm (30G); 
Natus Medical Incorporated, USA) were inserted under the skin 
with the active electrode at the vertex, the reference electrode 
at the ear being tested, and the ground electrode near the 
opposite ear. Biological signals were amplified (x1000), filtered 
(bandpass hardware filter: 1.0-8000 Hz; notch filter to remove 50 
Hz noise) (BrownLee, model 440, USA) and digitalised at a 
sampling rate of 100.000 Hz (Power 1401, Cambridge Electronic 
Design, Cambridge, UK). Acoustic stimuli were generated by Spike 
2 software (v. 7.07; Cambridge Electronic Design, Cambridge, UK), 
amplified (Argon Audio headphone amplifier, model HA1, Denmark) 
and presented through insert-earphones connected to hollow ear 
bars guiding the sound waves directly to the external auditory 
meatus. All tones were calibrated with a Bruel & Kjaer microphone 
(Sound level meter Type 2236; Microphone Type 4188) prior to ABR 
testing. 
 
Gabazine and local field potentials (Figure 4) 
 Surgical procedures. Mice were anesthetized with chloral 
hydrate (400 mg/kg i.p, followed by a maintenance dose of ≈ 1 
mg/kg/min i.p. using a perfusion pump). Body temperature was 
maintained at 37°C using a heating pad.  Single unit recordings 
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were carried out with glass micropipettes pulled from 2 mm 
capillary glass (World Precision Instruments, Sarasota, FL) on a 
Narishige (Tokyo, Japan) PE-2 pipette puller. Electrode descents 
were carried out in the mPFC at coordinates AP: + 2.1, L: -0.2-
0.4, DV: -1-2.5 mm. Stereotaxic coordinates were taken from 
bregma and duramater according to the mouse brain atlas (1). The 
signal was amplified (x10) with a Neurodata IR283 (Cygnus 
Technology Inc., Delaware Water Gap, PA), postamplified (x100) 
and filtered (band pass filter 30 Hz-10 kHz for spikes and 0.1-
100 Hz for local field potential) with a Cibertec 
amplifier/filter (Madrid, Spain) and computed using a DAT 
1401plus interface system Spike2 software (Cambridge Electronic 
Design, Cambridge, UK). At the end of experiments, mice were 
sacrificed by decapitation, the brains rapidly removed and 
prefrontal cortex (PFC) and caudate putamen (CP) dissected out on 
an ice-cold plate. Tissue samples were frozen at -20°C until 
analysed. 
Gabazine experiment. Spontaneous discharge rate of putative 
pyramidal neurons was analysed in control conditions and during 
local blockade of GABAA-Rs with the selective antagonist gabazine 
(SR95531, Sigma-Aldrich, St Louis, MO). Electrodes were filled 
with saline 2 M (impedances: 6-12 MΩ) or gabazine (20 mM) 
dissolved in 0.2 M NaCl. Gabazine was preferred to the classical 
GABAA antagonist bicuculline due to the non-selective action of 
the latter agent (2). Electrode tips were broken to a final 
resistance of 9-15 MΩ (electrode tip: 5-7µm diameter). Gabazine 
leaked from the recording electrode by passive diffusion to reach 
the recorded neuron, as shown previously for bicuculline (3;4). 
The onset of drug effects was very rapid, usually >10 s. Once a 
putative pyramidal neuron was encountered, a ≤ 5 min recording 
was made to obtain a reliable measure of spontaneous discharge 
rate after which the electrode was descended again. 
Local field potential recordings. Local field potential 
(LFP) recordings were performed in basal conditions and following 
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acute PCP treatment (10 mg/kg s.c., Sigma-Aldrich, Madrid, 
Spain). Off-line analysis was performed using the Spike 2 
software (Cambridge Electronic Design, Cambridge, UK). Power 
spectra were constructed by using Fast Fourier Transformation 
(FFT) of 1 min signal intervals (band-pass filter of 0.1-100 Hz) 
corresponding to baseline and PCP. Power resolution was 0.15 Hz. 
Results are presented as AUCs. 
 
 
Anatomy and biochemistry 
 
Gross anatomical and histological analyses (Figure A4) 
For gross neural morphological assessments, brains were 
fixed in 4% paraformaldehyde, post-fixed for 4 h, and embedded in 
paraffin. Additional brain-sets were prepared for free-floating 
sections. For free-floating sections, brains were placed in 30% 
sucrose until fully saturated following post-fixation. Paraffin 
embedded brains was cut at 4 μm. Free-floating sections were cut 
at 30 μm. Paraffin sections were deparaffinised and boiled in 
sodium citrate buffer (2x5 min) for antigen retrieval. All 
sections were treated with 1% H2O2 for 10 min to quench endogenous 
peroxidase activity and blocked with 5% serum plus 1% BSA and 
0.3% Triton X-100 for 30 min. Every 100 μm section was stained 
using NeuN (MAB377, Millipore) and parvalbumin (P3088, Sigma) 
antibodies. Colormetric stains (hemotoxylin/eosin and solochrome) 
were used to observe structure and myelination patterns. Primary 
antibodies were incubated overnight at 4°C followed by incubation 
with secondary biotinylated antibodies (Dako) for 1 h at room 
temperature. Following secondary antibody, sections were 
incubated with streptavidin-biotin complex (Vectastain) for 1 h 
before being developed with diaminobenzidine and mounted with 
Pertex (HistoLab).  
 
Western molecular weight analyses (Figure 3g/Table 2) 
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Tissue collection. WT and Df(h22q11)/+ mice were culled by 
cervical dislocation, the brains were removed, and the PFC, DStr 
and hippocampus were dissected and immediately frozen on dry ice 
before being stored at -80°C. 
Lysate preparation. Tissue was lysed with 10x volume of RIPA 
buffer (150 mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium 
deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) containing 
phosphatase and protease inhibitors (Thermo Scientific). Each 
sample was sonicated 3 times for 10 s and then centrifuged for 10 
min at 4°C (>10,000g). Protein concentration was measured on an 
Emax precision microplate reader (Molecular Devices, Sunnyvale, 
CA, USA) using the Pierce BCA protein assay kit (Thermo 
Scientific). 
Western molecular weight analyses. Simple Western molecular 
weight analyses were performed according to the ProteinSimple 
user manual. In brief, lysate samples were mixed with a master 
mix (ProteinSimple) to a final concentration of 1x sample buffer, 
1x fluorescent molecular weight markers, and 40 mM dithiothreitol 
(DTT) and then either heated at 95°C for 5 min or left at room 
temperature, depending on the optimised conditions for each 
primary antibody. The samples, blocking reagent, primary 
antibodies, HRP-conjugated secondary antibodies, chemiluminescent 
substrate, and separation and stacking matrices were dispensed to 
designated wells in a 384-well plate. After plate loading, the 
separation electrophoresis and immunodetection steps took place 
in the capillary system and were fully automated. Peggy–Simple 
Western analysis is carried out at room temperature, and 
instrument default settings were used except as specified below. 
Capillaries were first filled with separation matrix, followed by 
stacking matrix and approximately 40 nl of sample loading. During 
electrophoresis, proteins were separated on the basis of 
molecular weight through the stacking and separation matrices at 
250V for 40-45 min and then immobilized on the capillary wall 
using proprietary, photoactivated capture chemistry. The matrices 
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were then washed out. Capillaries were next incubated with a 
blocking reagent for 15 min, and target proteins were 
immunoprobed with primary antibodies, followed by HRP-conjugated 
secondary antibodies. Primary antibodies used were PSD-95 (Cell 
Signalling Technology (CST) #2507), Synaptophysin (CST #5461), 
Synapsin 1 (CST #2312), Drebrin (Medical and Biological 
Laboratories #D029-3), Gephyrin (Millipore #5725), NeuN 
(Millipore #N78), GFAP (CST #670), GluR1 (Anaspec #51516), GluR2 
(Millipore #10529), NR2A (Sigma-Aldrich #M264), NR2B (NeuroMab 
#75-101), VGluT1 (Synaptic systems #135303), GAD65/67 (Abcam 
#55412), GABAA α1 (Millipore #5592), KCC2 (Millipore #07-432) and 
VGAT (Synaptic Systems #131011). All primary antibodies were 
diluted in antibody diluent (ProteinSimple) with a 1:25, 1:50 or 
1:800 dilutions. The antibody incubation time was 120 or 180 min. 
Luminol and peroxide (ProteinSimple) were then added to generate 
chemiluminescence, which was captured by a charge-coupled device 
(CCD) camera. The digital image was analysed with Compass 
software (ProteinSimple), and the quantified data of the detected 
proteins was reported for the HET mice as percentage of WT 
signal, normalised to the housekeeping gene Pan Cadherin. Pan 
Cadherin was used as the housekeeping gene as it showed no 
significant difference between the sample groups, and is a very 
robust marker to run on the Peggy system, with a mean coefficient 
of variation (CV) below 20. Any markers that showed significant 
percentage change between genotypes in the original study was 
initially repeated using a new sample and master mix dilution. 
For cost and time limitations, a second replication study was run 
where all markers were measured using pooled samples. Here, the 
same 11 WT and 11 HET samples were pooled separately and run on 
the Peggy machine against each marker twice. 
 
Microdialysis (Figure 4) 
Drugs and reagents. HPLC reagents were of analytical grade 
and obtained from Merck (Darmstadt, Germany). Veratridine and 
Page 74 of 83
For Peer Review Only































































phenciclidyne hydrochloride (PCP) were purchased from Sigma-
Aldrich (Madrid, Spain) and nomifensine from Tocris (Madrid, 
Spain). Veratridine was dissolved in DMSO and nomifensine in 
artificial CSF (aCSF). Concentrated solutions (5 mM and 1 mM, 
respectively) were stored at -20°C and working solutions, diluted 
in aCSF at the stated concentrations, and prepared immediately 
before local application through the dialysis probe. PCP was 
dissolved in saline.  
Microdialysis procedure. A detailed description of the probe 
manufacture and microdialysis procedure can be found elsewhere 
(5). Anesthetized mice (sodium pentobarbital, 30 mg/kg, i.p.) 
were stereotaxically implanted with concentric microdialysis 
probes equipped with a Cuprophan membrane (1.5 mm long) in the 
DStr at AP: +0.5, ML −1.7, DV −4.5 mm from Bregma and skull 
surface (1). Microdialysis was performed in freely moving mice 
>20 h after surgery. Probes were perfused with aCSF (125 mM NaCl, 
2.5 mM KCl, 1.26 mM CaCl2, 1.18 mM MgCl2) and pumped at 1.5 
µl/min. Dialysate fractions were collected every 20 min. After 
collection of baseline dialysate fractions, a local pulse (20 
min) of the depolarizing agent veratridine (50 μM) was 
administered by reverse dialysis. Following recovery of basal 
values, the DA uptake inhibitor nomifensine (50 μM) was applied 
by reverse dialysis. On the following day, the same mice were 
used to examine the effect of systemic administration of PCP (2.5 
+ 2.5 mg/kg s.c.) on extracellular DA levels in the striatum. 
After a 60 min (veratridine and nomifensine) or 180 min (PCP-
treated animals) stabilisation period, 4-5 fractions were 
collected to obtain basal values before local (reverse dialysis) 
or systemic drug administration. Thereafter, successive 20 min 
dialysate samples were collected. The concentration of DA in 
dialysate samples was determined by HPLC, using a modification of 
a previously described method (6). Brain dialysates were 
collected on micro vials containing 5 µl of 10 mM perchloric acid 
and were rapidly injected into the HPLC. DA was amperometrically 
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detected at 5–7.5 min with an absolute limit of detection of 2–
3 fmol/sample using an oxidation potential of +0.75 V (Hewlett-
Packard 1049 amperometric detector). Fractions 4-5 were used to 
determine the concentration of dopamine (DA), glutamate (Glu), 
homovanilic acid (HVA) and 3,4-dihidroxyphenylacetic acid (DOPAC) 
in basal conditions (5;7;8).  
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Supplementary Figure A3. Characterisations of Df(h22q11)/+ and WT 
littermates. (a) Birth ratios. The Df(h22q11)/+ mutant has 
decreased in utero survival (Total N = 117, WT N = 70, TG N = 47; 
p = 0.047, binomial distribution). (b) Brain weight. No effect of 
genotype (F1,16 = 2.107, p = 0.166). (c). PFC parvalbumin 
positive cells. No effect of genotype (F1,12 = 0.650, p = 0.436). 
(d) Basal locomotor activity. No effect of genotype on 60min 
open-field activity (F1,93 = 0.618, p = 0.434) (e). Rotarod. No 
effect of genotype (genotype: F1,18 = 0.343, p = 0.565; genotype 
× session F3,54 = 1.058, p = 0.374). (f) Hot plate test. No 
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effect of genotype (F1,20 = 0.219, p = 0.645) or genotype × 
temperature interaction (F1,40 = 0.906, p = 0.412). (g) Elevated 
plus maze. No effect of genotype on percent time in open arms 
(F1,22 = 0.018, p = 0.894). (h). Bright open field (120 lux). No 
effect of genotype (F1,90 = 0.000212, p = 0.988) or genotype × 
zone (F2,90 = 0.557, p = 0.575). (i) Beam-walking.  No effect of 
genotype on time spent on beam (F1,30 = 0.006, p = 0.938) foot 
slips (F1,30 = 0.008, p = 0.929) or falls (F1,30 = 0.338, p = 
0.565). (j) PPI inter-trial activity (ITA). No effect of genotype 
in 6 independent cohorts aged between 6-21 weeks (p ≥  0.129). 
Asterisk denote differences at which p < 0.05
Page 78 of 83
For Peer Review Only
































































Supplementary Figure A4. Anatomical and 
histological evaluation of 10-week old WT 
(left panels) and Df(h22q11)/+ (right panels) 
littermates. (a-b) Cortical NeuN 
immunoreactivity. (c) Dorsal hippocampal 
solochrome stain. (d) Parvalbumin 
immunoreactivity in PFC. (e). Parvalbumin 
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Deletion Dgcr2-Hira Dgcr2-Hira Dgcr2-Hira Dgcr14-Ufd11 Znf74-Ctp 





Test Battery      





Brain weight x - x
(9)
 - - 
Beam walk x - - - - 











 - - - 









x - - - - 
Bright open x - - - - 
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Supplementary Table A1. Summary of results from basic charactarisations for the 
Df(h22q11)/+ mutant and other 22q11.2DS mouse models. ↓ decreased, ↑ increased, ╳ no 
effect, - no data. 
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